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Turning All Available Data Into Useful Information*Robert A. Harrington, MDW e are in the era of “big data” in cardiovas-cular medicine (1). This brings bothexcitement and challenges to the clini-
cian who is making dozens, if not hundreds, of clin-
ical decisions every day in the care of individual
patients. Enormous amounts of data are available on
each patient, much of which is increasingly available
in electronic health records (EHR), but there are also
data from clinical trials and observational studies on
population-level outcomes associated with certain
diagnostic and therapeutic options. Providers are
expected to know about all of this information, assess
its quality, aggregate it, analyze it, and interpret it
in a way that increases the likelihood of excellent
outcomes for each patient. This is a daunting task to
accomplish for a single patient, and yet it must be
repeated almost continuously in the context of a
busy clinical practice.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have partnered to
create a series of clinical practice guidelines (CPGs) to
help clinicians review the available evidence and
make treatment decisions by building on evidence-
based recommendations (2). The CPG efforts have
been supplemented by resources that assist in clinical
decision making, such as appropriate use criteria,
which can serve as tools for informed conversations
with patients about treatment options (3). Payers
deciding on reimbursement suitability and whether
to incentivize healthcare systems to provide high-* Editorials published in the Journal of the American College of Cardiology
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Events (Santa Rosa, California).quality care also have used such tools. Clearly, there
is a societal desire to get the most complete quanti-
tative information to patients and their providers, so
that the best evidence-based decisions can be made in
the quest for optimal patient outcomes.
The care of patients with coronary artery disease
involves making multiple decisions about diagnosis
and risk stratiﬁcation, medical treatments, and
revascularization options. Risk scores have been
developed to aid in that decision-making process by
providing tools that quantify a patient’s likelihood of
having the disease, contribute insight into the risk of
subsequent clinical events (such as cardiac mortality
or ischemic events like myocardial infarction), esti-
mate the likelihood of gaining incremental beneﬁt
from certain medical therapies, and aid in deter-
mining the appropriateness of 1 type of revascu-
larization procedure over another (percutaneous
coronary intervention [PCI] vs. coronary artery
bypass grafting [CABG]). For those patients under-
going revascularization procedures, risk scores have
been developed that provide an estimate of proce-
dural or surgical adverse risks (4,5). All of these scores
have the ultimate goal of being useful to the clinician
in discussions with their patient, so decisions
regarding their care can be thoughtful, evidence-
based, and potentially tailored to the individual’s
characteristics. This is the essence of informed clin-
ical decision making. Recent controversy about the
risk calculator released as part of the ACC/AHA Pre-
vention Guidelines reﬂects the intense interest from
multiple stakeholder groups in the construction of
useful risk scores.
The SYNTAX score, a risk assessment score built
from coronary angiographic variables, has been
shown to be useful in separating patients with coro-
nary artery disease into low-, intermediate-, and
Harrington J A C C V O L . 6 4 , N O . 5 , 2 0 1 4
From Big Data to Useful Information A U G U S T 5 , 2 0 1 4 : 4 3 3 – 5
434high-risk groups (6). Additionally, the SYNTAX score
suggests cutoffs, indicating which patients gain
more beneﬁt (i.e., have better clinical outcomes) with
1 form of revascularization versus another. Most
importantly, the analyses from SYNTAX support the
notion that patients with the most complex coronary
anatomy (high SYNTAX risk score) preferentially
beneﬁt from CABG more than PCI. It is this ability of
the SYNTAX score to discriminate reasonably well the
beneﬁts of a therapy for a group of patients that has
resulted in its inclusion in both the American and
European revascularization guidelines (7,8). In this
issue of the Journal, Zhang et al. (9) extend theSEE PAGE 423ﬁndings from the original SYNTAX trial by reporting
the results of a series of analyses comparing site
investigator–reported SYNTAX scores (sSS) with core
laboratory–assessed SYNTAX scores (cSS). In these
analyses, the sSS performs less well than the cSS in
discriminating among the 3 risk groups (low, inter-
mediate, and high). Of note, when clinical variables
are combined with the angiographic variables into a
new risk score, SSII, the concordance index is similar
whether using the sSS or the cSS as the angiographic
piece of the risk equation. The authors conclude that
appropriate training is necessary to reduce variability
and improve performance in the assessment of the SS.
Also, they deduce that inclusion of the clinical vari-
ables as part of the patient assessment is critical for
optimal risk scoring and for guiding the revasculari-
zation strategy.
Clinical trials frequently use core laboratory
assessment or central review for interpreting images
and laboratory measures as well as for adjudicating
clinical events, such as myocardial infarction, stroke,
or bleeding (10). Analyses from clinical studies,
including modeling for outcomes, typically use cen-
trally reviewed and adjudicated data, as these data
have been systematically evaluated with less bias and
more attention to protocol deﬁnitions. But once these
published analyses are to be used in routine clinicalpractice (i.e., outside the controlled environment of a
clinical study), locally derived and deﬁned data must
be used in the risk scoring systems by practical neces-
sity. In making clinical decisions, practitioners heu-
ristically incorporate all sorts of data (clinical, imaging,
laboratory, and so on) from the individual patient (11).
Formal, validated risk scores can aid the clinician (and
the patient) in the decision-making process, but such
scores need to be statistically robust (12) while also
having face validity and being easy to use.
The assessment of the SS score (sSS) at the site
suffers from weakness in its discriminatory ability,
although the authors note that performance will
likely improve through appropriate training. Formal
incorporation of the clinical variables (something the
practitioner does as a matter of course) strengthens
the score’s performance (c-index ¼ 0.744). For the
sSS-derived SSII to be useful at the point of care, it
needs the addition of tools and applications that will
facilitate its incorporation into the clinical workﬂow.
Increasingly, clinicians want to use smartphone ap-
plications that can be readily accessed at the point of
care delivery. A good example is the recently released
atherosclerosis risk calculator (13).
Ultimately, the most value will be in having EHR
data integrated seamlessly with specialized data on
genotyping, imaging, other laboratory data, and
eventually, even wearable sensor data. Risk assess-
ment and treatment decision algorithms will be
updated and recalculated continuously and fed back to
providers at the point of care, so that they can integrate
each patient’s values and preferences to place them
in their individual social and environmental context
to arrive at decisions that best ﬁt that individual. At
that point, “big data” will be more than a buzz phrase;
it will have turned into useful information.
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